Chengda Pharmaceuticals (301201.SZ): Dapagliflozin API approved by CDE.

14/11/2024

GMT Eight

Chengda Pharmaceuticals (301201.SZ) announced that the company has received the approval and issuance of the chemical raw materials for Dapagliflozin by the National Medical Products Administration in the "Chemical Raw Materials Market Application Approval Notice". The related indications for the drug are: on the basis of diet and exercise, this product can be used as a monotherapy for improving blood sugar control in adult patients with type 2 diabetes. This product is not suitable for the treatment of type 1 diabetes or diabetic ketoacidosis.

Ningbo Shimao Energy (605028.SH): Termination of Share Issuance for Asset Purchase, Resumption of Trading Tomorrow

Wingtech Technology (600745.SH): Wuxi Guolian Integrated Circuit Investment Center (Limited Partnership) has cumulatively reduced its holdings in the company by 1%.

Contact: contact@gmteight.com

Chengda Pharmaceuticals (301201.SZ): Dapagliflozin API approved by CDE.

RECOMMEND

Powell Hawkish! Two-year US Treasury yield rises, traders cut bets on December rate cut.

China Securities Co., Ltd.: Shared resonance of capital and liabilities improvement continues to focus on the transformation of the product structure of insurance companies to improve the quality of liabilities.

LENOVO GROUP (00992) Achieves Several New Records in First Half of the Year. Net profit attributable to equity holders reached $602 million, an increase of 41% year-on-year.